CytoSorbents says real-world analysis shows 37% drop in severe bleeding with CytoSorb in urgent CABG patients on ticagrelor
CTSO•CTSO•CTSO•CTSO•Management expects the data to support a new FDA De Novo filing for DrugSorb-ATR in early 2027.
Bleeding-related resource use also eased, with no serious device-related safety issues reported.
CytoSorbents says new real-world evidence on CytoSorb use in urgent CABG patients recently exposed to ticagrelor was presented at the ESC Congress 2026 on Aug. 29, 2026.
The matched analysis showed materially lower rates of severe perioperative bleeding versus comparable patients operated without the device.
